These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01. Eifel PJ; Winter K; Morris M; Levenback C; Grigsby PW; Cooper J; Rotman M; Gershenson D; Mutch DG J Clin Oncol; 2004 Mar; 22(5):872-80. PubMed ID: 14990643 [TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant chemotherapy with vincristine and cisplatin followed by radical hysterectomy and pelvic lymphadenectomy for FIGO stage IB bulky cervical cancer: a Gynecologic Oncology Group pilot study. Eddy GL; Manetta A; Alvarez RD; Williams L; Creasman WT Gynecol Oncol; 1995 Jun; 57(3):412-6. PubMed ID: 7774847 [TBL] [Abstract][Full Text] [Related]
4. Postoperative adjuvant concurrent chemoradiotherapy improves survival rates for high-risk, early stage cervical cancer patients. Ryu HS; Chun M; Chang KH; Chang HJ; Lee JP Gynecol Oncol; 2005 Feb; 96(2):490-5. PubMed ID: 15661240 [TBL] [Abstract][Full Text] [Related]
5. Prognostic factors affecting the outcome of early cervical cancer treated with radical hysterectomy and post-operative adjuvant therapy. Liu MT; Hsu JC; Liu WS; Wang AY; Huang WT; Chang TH; Pi CP; Huang CY; Huang CC; Chou PH; Chen TH Eur J Cancer Care (Engl); 2008 Mar; 17(2):174-81. PubMed ID: 18302655 [TBL] [Abstract][Full Text] [Related]
6. Ten-year survival of patients with locally advanced, stage ib-iib cervical cancer after neoadjuvant chemotherapy and radical hysterectomy. Hwang YY; Moon H; Cho SH; Kim KT; Moon YJ; Kim SR; Kim DS Gynecol Oncol; 2001 Jul; 82(1):88-93. PubMed ID: 11426967 [TBL] [Abstract][Full Text] [Related]
7. Rethinking the use of radiation and chemotherapy after radical hysterectomy: a clinical-pathologic analysis of a Gynecologic Oncology Group/Southwest Oncology Group/Radiation Therapy Oncology Group trial. Monk BJ; Wang J; Im S; Stock RJ; Peters WA; Liu PY; Barrett RJ; Berek JS; Souhami L; Grigsby PW; Gordon W; Alberts DS; ; ; Gynecol Oncol; 2005 Mar; 96(3):721-8. PubMed ID: 15721417 [TBL] [Abstract][Full Text] [Related]
8. Treatment results of adjuvant chemotherapy after radical hysterectomy for intermediate- and high-risk stage IB-IIA cervical cancer. Takeshima N; Umayahara K; Fujiwara K; Hirai Y; Takizawa K; Hasumi K Gynecol Oncol; 2006 Nov; 103(2):618-22. PubMed ID: 16777200 [TBL] [Abstract][Full Text] [Related]
9. Optimal management of locally advanced cervical carcinoma. Keys H; Gibbons SK J Natl Cancer Inst Monogr; 1996; (21):89-92. PubMed ID: 9023835 [TBL] [Abstract][Full Text] [Related]
10. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. Morris M; Eifel PJ; Lu J; Grigsby PW; Levenback C; Stevens RE; Rotman M; Gershenson DM; Mutch DG N Engl J Med; 1999 Apr; 340(15):1137-43. PubMed ID: 10202164 [TBL] [Abstract][Full Text] [Related]
11. The prognostic factors for patients with early cervical cancer treated by radical hysterectomy and postoperative radiotherapy. Tsai CS; Lai CH; Wang CC; Chang JT; Chang TC; Tseng CJ; Hong JH Gynecol Oncol; 1999 Dec; 75(3):328-33. PubMed ID: 10600284 [TBL] [Abstract][Full Text] [Related]
12. Preoperative concurrent radiation therapy and chemotherapy for bulky stage IB2, IIA, and IIB carcinoma of the uterine cervix with proximal parametrial invasion. Huguet F; Cojocariu OM; Levy P; Lefranc JP; Darai E; Jannet D; Ansquer Y; Lhuillier PE; Benifla JL; Seince N; Touboul E Int J Radiat Oncol Biol Phys; 2008 Dec; 72(5):1508-15. PubMed ID: 18676093 [TBL] [Abstract][Full Text] [Related]
13. Extent of disease as an indication for pelvic radiation following radical hysterectomy and bilateral pelvic lymph node dissection in the treatment of stage IB and IIA cervical carcinoma. Monk BJ; Cha DS; Walker JL; Burger RA; Ramsinghani NS; Manetta A; DiSaia PJ; Berman ML Gynecol Oncol; 1994 Jul; 54(1):4-9. PubMed ID: 8020837 [TBL] [Abstract][Full Text] [Related]
14. Chemotherapy versus radiotherapy versus observation for high-risk cervical carcinoma after radical hysterectomy: A randomized, prospective, multicenter trial. Lahousen M; Haas J; Pickel H; Hackl A; Kurz C; Ogris H; Stummvoll W; Winter R Gynecol Oncol; 1999 May; 73(2):196-201. PubMed ID: 10329034 [TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant chemotherapy followed by radical surgery and radiotherapy vs. pelvic irradiation in patients with cervical cancer FIGO stage IIB - IVA. Kornovski Y; Gorchev G J BUON; 2006; 11(3):291-7. PubMed ID: 17309152 [TBL] [Abstract][Full Text] [Related]
16. Histopathological findings in postoperative specimens in cervical cancer patients with stages IB2-IVA after neoadjuvant chemotherapy and preoperative plus postoperative radiotherapy. Kornovski Y; Gorchev G J BUON; 2007; 12(1):57-63. PubMed ID: 17436403 [TBL] [Abstract][Full Text] [Related]
17. [Preoperative concurrent radiation therapy and chemotherapy for operable bulky carcinomas of uterine cervix stages IB2, IIA, and IIB with proximal parametrial invasion]. Lerouge D; Touboul E; Lefranc JP; Uzan S; Jannet D; Moureau-Zabotto L; Genestie C; Antoine M; Jamali M Cancer Radiother; 2004 Jun; 8(3):168-77. PubMed ID: 15217584 [TBL] [Abstract][Full Text] [Related]
18. Adjuvant small field pelvic radiation for patients with high risk, stage IB lymph node negative cervix carcinoma after radical hysterectomy and pelvic lymph node dissection. A pilot study. Kridelka FJ; Berg DO; Neuman M; Edwards LS; Robertson G; Grant PT; Hacker NF Cancer; 1999 Nov; 86(10):2059-65. PubMed ID: 10570432 [TBL] [Abstract][Full Text] [Related]
19. Postoperative radiation therapy for stage IB-IIB carcinoma of the cervix with poor prognostic factors. Uno T; Ito H; Itami J; Yasuda S; Isobe K; Hara R; Sato T; Minoura S; Shigematsu N; Kubo A Anticancer Res; 2000; 20(3B):2235-9. PubMed ID: 10928184 [TBL] [Abstract][Full Text] [Related]
20. Treatment of ("bulky") stage IB cervical cancer with or without neoadjuvant vincristine and cisplatin prior to radical hysterectomy and pelvic/para-aortic lymphadenectomy: a phase III trial of the gynecologic oncology group. Eddy GL; Bundy BN; Creasman WT; Spirtos NM; Mannel RS; Hannigan E; O'Connor D Gynecol Oncol; 2007 Aug; 106(2):362-9. PubMed ID: 17493669 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]